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Abstract
Purpose: The aberrant expression of miR-221 is a hallmark of
human cancers, including hepatocellular carcinoma (HCC), and
its involvement in drug resistance, together with a proved in vivo
efficacy of anti-miR-221 molecules, strengthen its role as an
attractive target candidate in the oncologic field. The discovery
of biomarkers predicting the response to treatments represents a
clinical challenge in the personalized treatment era. This study
aimed to investigate the possible role of miR-221 as a circulating
biomarker in HCC patients undergoing sorafenib treatment as
well as to evaluate its contribution to sorafenib resistance in
advanced HCC.
Experimental Design: A chemically induced HCC rat model
and a xenograft mouse model, together with HCC-derived cell
lines were employed to analyze miR-221 modulation by Sorafe-
nib treatment. Data from the functional analysis were validated in
tissue samples from surgically resected HCCs. The variation of
circulating miR-221 levels in relation to Sorafenib treatment were
assayed in the animal models and in two independent cohorts of
patients with advanced HCC.
Results: MiR-221 over-expression was associated with Sorafe-
nib resistance in two HCC animal models and caspase-3 was
identified as its target gene, driving miR-221 anti-apoptotic activ-
ity following Sorafenib administration. Lower pre-treatmentmiR-
221 serum levels were found in patients subsequently experienc-
ing response to Sorafenib and an increase of circulating miR-221
at the twomonths assessmentwas observed in responder patients.
Conclusions:MiR-221 might represent a candidate biomarker
of likelihoodof response to Sorafenib inHCCpatients to be tested
in future studies. Caspase-3 modulation by miR-221 participates
to Sorafenib resistance. ClinCancer Res; 23(14); 3953–65.2017AACR.
Introduction
The up-regulation of miR-221 along with its oncogenic activity
were previously reported in hepatocellular carcinoma (HCC;
refs. 1–3), as well as in other cancers, such as glioblastoma
(4, 5), papillary thyroid carcinoma (6, 7), pancreatic cancer
(8), prostate (9), melanoma (10), breast (11), kidney, and blad-
der cancers (12).Onco-miR-221upregulation canbe considered a
hallmark of cancer. We have also shown its tumor-promoting
functions in the liver of a miR-221 transgenic mouse, confirming
its role as a therapeutic candidate (13).
Molecular mechanisms sustaining miR-221 oncogenic func-
tions rely upon the regulation of cell proliferation (1) and
impairment of apoptosis (3, 5). In addition, miR-221 plays an
important role in the modulation of response to anticancer
treatments through the regulation of key oncogenic factors
such as the TP53–MDM2 axis (14), TIMP3 (15), and PTEN
(16) molecules.
Even though sorafenib represents the standard of care for
advanced HCC and it is the only recommended treatment in this
setting, there is no biomarker helpful in the prediction of sensi-
tivity to this treatment. However, heterogeneous responses may
be observed across patients treated by sorafenib.
The discovery of novel target candidates increasing the effi-
cacy of anticancer strategies and the identification of noninva-
sive biomarkers in liquid biopsies are two important clinical
challenges in the oncologic field. It was widely demonstrated
that microRNAs are optimal biomarkers due to their high
stability in biologic fluids and the availability of easy detection
methods (17, 18).
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Here, we explored, by using an in vivo and in vitro approach, the
role ofmiR-221 as a tissue and circulating biomarker in the setting
of sorafenib treatment. To this aim, we used two HCC models, a
diethylnitrosamine (DEN)-induced HCC rat model and a xeno-
graft mouse model, as well several HCC-derived cell lines. More-
over, we tested the circulating levels of miR-221 as a candidate
noninvasive biomarker associated with response to sorafenib
treatment in advanced HCC, both in animal models and in a
small and preliminary cohort of HCC patients. Finally, molecular
mechanisms sustaining the role of miR-221 as an innovative
therapeutic target in HCC were investigated, and caspase-3 mod-
ulation was assessed as a critical factor.
Patients and Methods
Patients
HCC and cirrhotic tissues were obtained from 60 randomly
selected patients (45 males and 15 females, median age  SD,
70.0 8.5 years; range, 49–82 years) undergoing liver resection
for HCC. Tissues were collected at surgery and stored as pre-
viously described (19). Local ethics committee of St. Orsola-
Malpighi University Hospital approved the study, and all
patients signed an informed consent. Histopathologic grading
was scored according to Edmondson and Steiner criteria (20).
No patient received anticancer treatment prior to surgery.
Antiviral treatment was administered to HBV-infected patients
only. No HCV-infected patient received antiviral treatment
except for interferon-based regimens performed at least 3 years
before surgery. Eight normal liver tissues were obtained from
patients undergoing liver surgery for traumatic lesions (5 cases)
or hemangioma resection (3 cases). The characteristics of
patients are detailed in Supplementary Table S1.
A further cohort of 93 patients with advanced HCC without
extrahepatic metastases were tested for miR-221 circulating
levels. Fifty patients from Bologna center (23 responders and
27 nonresponders at 2 months) were tested before treatment
start. Among these, 28 patients (12 responders and 16 non-
responders) were assayed before treatment and at the 2 months
assessment. The remaining 43 patients (17 with stable disease
and 26 patients with disease progression at 2 months) were
tested for circulating miR-221 levels before treatment start (43
cases) and at the 2 months assessment (31 of 43 patients).
These 43 patients were enrolled by both the Bologna Center
and the Department of Medical Oncology of Meldola's Center
(Italy) and were considered as an independent validation
cohort. Patients' characteristics are detailed in Supplementary
Table S2 and Supplementary Fig. S1.
DEN-HCC rat model
Male Wistar rats (Harlan) received DEN (Sigma-Aldrich) in
the drinking water (100 mg/L) for 8 weeks. Two weeks later the
end of DEN treatment, animals were weekly monitored by
ultrasound imaging (US; MyLab70 XVG, Esaote; ref. 21). A
first group of animals (N ¼ 18) was euthanized 1 or 2 months
after the end of DEN treatment, when the major diameter of at
least one HCC nodule reached a dimension of 10 mm at US. A
second group of animals (N ¼ 10) received sorafenib intragas-
trically for 21 days (10 mg/kg of body weight), starting when a
2- to 3-mm nodule was evident at US. Animals were segregated
in responder and nonresponder groups according to US and
histopatologic examination. Two untreated animals were used
as control. At sacrifice, HCC nodules and surrounding liver
were collected for molecular biology and immunohistochem-
istry analyses. Twenty-three and 16 HCC nodules were collected
in the untreated and treated groups, respectively. At sacrifice,
blood withdrawal was obtained from 13 of 18 untreated and 7
of 10 sorafenib treated rats. Serum was achieved by centrifu-
gation of blood samples at 4,000 rpm for 10 minutes at 4C. All
animals received human care in accordance with the criteria
published by the National Institutes of Health. Local ethics
committee approved the research protocol (14/70/12).
HCC mice models
For the xenograft model, 3.0 million of Huh-7 cells were
injected into both flanks of NOD/SCID (CB17PRKDC/J) female
mice (N¼15animals). Fourweeks following cell injection, tumor
masses were weeklymonitored byUS examination, and when the
tumors reached a volume of about 40 to 50mm3 (width length
 height/2) mice were randomized into two groups. One group
(N ¼ 6) received intragastrically a dose of 60 mg/kg body weight
of sorafenib for 21 days, while the other group (N ¼ 9) received
only the vehicle (75% water, 12.5% absolute ethanol, and 12.5%
cremophor EL; Sigma-Aldrich). Mice were euthanized one day
after the endof the treatment or, in the case of theuntreated group,
when the tumor mass exceeded the volume of about 1 cm3. At
sacrifice, tumormasses were collected for bothmolecular biology
and histopathology analyses. At sacrifice, blood withdrawal was
obtained from all mice of the vehicle-treated group and from 5 of
6 sorafenib-treated animals. Serum samples were obtained as
above described. Local ethics committee approved the research
protocol (23/79/14).
The miR-221 transgenic mouse model was performed as
previously described (13, 14). Protein samples were extracted
from liver tissues derived from 25 transgenic (TG) and 16 wild-
type (WT) animals. Ten TG mice were treated by hydrodynamic
tail vein injection with anti-miR-221 oligonucleotides
(300 mg/mouse) or with vehicle only (saline) for 48 hours. Four
more animals were treated with anti-miR-221 oligonucleotides
or with vehicle only in the presence of sorafenib treatment
(intragastrical administration, 10 mg/kg) for 48 hours.
Cell culture and treatments
HepG2, Hep3B, and PLC/PRF/5 cells were cultured with Eag-
les's Minimum Essential Medium while SNU398, SNU449,
SNU182, SNU475, and Huh-7 were cultured with RPMI-1640
(Life Technologies). Media were supplemented with 10% FBS, 2
mmol/L L-glutamine and 1 penicillin/streptomycin (Life Tech-
nologies). All the cell lines, except Huh-7, were purchased from
ATCC. Huh-7 cells are from Prof. Alberti's laboratory, University
of Padua, Italy. Cell clones used for experiments were previously
authenticated. Cells were treated with 5.0 mmol/L sorafenib-
tosylate (Bayer) for 48 hours. All experiments were performed
in triplicate.
Cells were also treated with 1.0 mmol/L of PI3Ka/d inhibitor
(GDC-0941), Raf inhibitor (PLX-4720), and VEGFR2 inhibitor
(ZM323881) for 48 hours (Selleckchem).
Cell transfection
HCC cells were transfected with 100 nmol/L of pre-miR-221,
anti-miR-221, or Negative Control#1 precursor and inhibitor
miRNAs (Ambion). BMF and caspase-3 small interfering RNA
pools (Trifecta RNAi Kit, IDT) were used at a concentration of 20
nmol/L for 24 and 48 hours. Oligonucleotide transfection was
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performed by using Lipofectamine 2000 (Life Technologies)
according to the manufacturer's instructions.
Stable transfection
For miR-221 overexpression in Huh-7 cells, the DNA sequence
of mature miR-221 was inserted into the pGFP-V-RS retroviral
vector (OriGene Technologies). The cells were infected and select-
ed as previously described (14).
Luciferase activity assay
The 30UTR region of human CASP3 gene was amplified by PCR
using primers and conditions reported in Supplementary Table
S3. A luciferase reporter assay of pGL3 30UTR-containing vector
was performed in HepG2 and SNU449 cells as previously
reported (22).
Caspase 3/7 activity assay and viability assay
Apoptosis activation and cell viability were evaluated in sor-
afenib-treated HCC cells by using Caspase-Glo 3/7 and Cell-titer-
Glo assays (Promega) according to the manufacturer's instruc-
tions. Each sample was analyzed in quadruplicate.
Real-time PCR and RT-PCR
MiRNA-221-3p expression inHCC cells and tissue sampleswas
evaluated by the TaqMan MicroRNA Assay (ID: 000524; Applied
Biosystems), as previously described (19). RNU6B (ID: 001093)
was used as housekeeping gene for human samples, whereas 4.5S
RNA(H) (ID: 001717) and snoRNA412 (ID: 001243) were used
for samples of rat and mouse origin, respectively. A pool of RNAs
from twoHCC cell lines or twoHCC rat livers or twomouse livers
was used as reference sample for the 2DDCt method for the
quantification of samples of human or rat or mouse origin,
respectively.
CASP3, BMF, AFP, EpCAM, CK19, and MYC mRNAs were
quantified by both semi-quantitative PCR and SYBR-green
(Bio-Rad Laboratories) Real-time PCR analyses. b-Actin expres-
sion was considered for gene normalization. Real-time PCR
experiments were run in triplicate. Primers and conditions are
detailed in Supplementary Table S4.
Serum and exosome miRNA extraction
Isolation of circulating miRNAs from exosomes and cell
culture supernatant of untreated and sorafenib-treated HCC
cells was executed by an ultracentrifugation-based protocol as
previously reported (23). Total RNA was isolated from 200 mL
of serum, cell culture supernatant, exosomes enriched or
depleted fractions by using MiRNeasy Serum/Plasma Kit (Qia-
gen). Briefly, 12.5 fmol of a synthetic RNA corresponding to cel-
miR-39 sequence (Ambion) were added to each sample after
Qiazol addition. RNA was suspended in 35 mL of DEPC water
and used at a 1:3 dilution for qPCR quantification of miR-221
and cel-miR-39.
Western blot
Thirty micrograms of whole protein extracts from cells and
tissues was subjected to vertical electrophoresis, transferred to a
nitrocellulose membrane (GE Healthcare) and assayed with
antibodies reported in Supplementary Table S5. Digital images
of X-ray films were quantified by ChemiDoc XRSþ (Image Lab
Software, Bio-Rad). Western blot analysis was performed in
triplicate.
Flow cytometry analysis
Transfected HCC cells were treated with 5 mmol/L sorafenib for
48 hours. Detection of apoptotic cells was performed in triplicate
by flow cytometry (FACSaria cell sorter, BD Biosciences) with
Annexin V/Propidium Iodide detectionkit (Bender MedSystems).
Statistical analysis
Differences between groups were analyzed using paired or
unpaired Student t test, for in vitro assays and for the analysis of
HCC-related variables, including miR-221 and caspase-3 expres-
sion in primary tumors as well as circulating miR-221 levels.
Pearson correlation coefficient was used to explore relationships
between two variables. In vitro experiments were performed
in triplicate, and the mean values were used for the statistical
analysis. Reported P values were two-sided and considered
statistically significant when lower than 0.05. Statistical calcula-
tionswere executed using SPSS version 15.0 (SPSS inc). ,P<0.05;
, P < 0.01; , P < 0.001.
Results
High intratumor miR-221 levels are associated with sorafenib
resistance in HCC animal models
The role of onco-miR-221 in hepatocarcinogenesis (13, 19, 24)
and response to treatments inHCC is documented (14–16).Here,
we used twoHCC animal models to investigate miR-221 involve-
ment in sorafenib resistance.
The first animal model is a chemically induced HCC rat model
displaying miR-221 overexpression in tumor tissue in 65% of
cases, with a mean increase of 2.8-fold in HCC nodules (N¼ 23)
when compared with matched surrounding liver (N ¼ 16; Fig.
1A). Notably, miR-221-deregulated expression observed in this
model reflects findings reported in human HCC (19). Moreover,
the nonneoplastic liver tissue of DEN-treated animals displays no
difference in miR-221 expression when compared with healthy
control rats, ruling out miR-221 modulation by DEN.
Following sorafenib administration, HCC nodules (N ¼ 16)
were considered as responders or nonresponders, based on US
monitoring performed weekly during the follow-up after DEN
discontinuation and histopathologic examination at sacrifice
(Supplementary Fig. S2). QPCR analysis showed higher intratu-
mor miR-221 levels in nonresponder versus responder rat HCCs
(Student t test: P ¼ 0.0013; Fig. 1B), suggesting that miR-221
might be implicated in sorafenib resistance. To characterize if
sorafenib resistance might be related to the expression of specific
oncogenes, AFP, EPCAM, CK19, and MYC mRNA levels were
analyzed in treated HCC animals. Higher EPCAM mRNA were
detected in HCC nodules non-responding to sorafenib with
respect to the responder group (Student t test: P ¼ 0.0011; Fig.
1C), while no difference was detected for AFP, CK19, and MYC
expression (Supplementary Fig. S3A–S3C).
The second animal model was a xenograft mouse model
obtained by subcutaneous injection of Huh-7 cells into animal
flanks. This model was chosen because it displays a relevant
response to sorafenib treatment, which is easily assessable by US
examination (25). In this model, sorafenib administration deter-
mined a reduction of tumor size of 3.5-fold with respect to
vehicle-treated mice (mean SD: 238 119 vs. 836 490mm3;
Student t test:P¼0.0062; Fig. 1D). Similarly, a 1.6-fold increase in
tumor doubling time was observed in sorafenib-treated mice in
comparison with controls (mean  SD: 4.3  2.0 vs. 6.9  0.9
mm3; Student t test, P ¼ 0.0044; Fig. 1E). An inverse correlation
MiR-221 Regulates Sorafenib Response in HCC
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was foundbetween tumor size and tumor doubling time (Pearson
correlation, P ¼ 0.002; Supplementary Fig. S3D).
When miR-221 levels were assessed in the tumor masses
from untreated animals, no correlation was found with respect
to size and tumor doubling time. Conversely, in sorafenib-
treated mice a positive correlation was detected between miR-
221 expression and tumor size (Pearson correlation: R¼ 0.66; P
¼ 0.048; Fig. 1F), letting us to hypothesize that also in this
model high miR-221 levels might be associated with sorafenib
resistance.
Circulating miR-221 levels predict response to sorafenib
Because higher miR-221 tissue levels are associated with
sorafenib resistance in the rat HCC model and with increased
tumor mass in the xenograft model, we investigated the rela-
tionships between tissue and circulating miR-221 levels in
these models, to define its role as a possible circulating
biomarker.
MiR-221 expression was quantified in serum samples and
tumor tissues from 13 DEN-HCC–untreated rats. As shown
in Fig. 2A, a correlation was found between miR-221 levels in
HCC tissue and serumsamples (Pearson correlation: R¼0.58;P¼
0.045). Only the larger nodule was considered in animals bearing
more than one HCC, hypothesizing that it might be the main
source of miRNAs release into the bloodstream. When consider-
ing more nodules in rats with a multinodular HCC, a positive
correlation, even though not statistically significant, was con-
firmed between tissue and circulating miR-221 levels (Pearson
correlation: R ¼ 0.42; P ¼ 0.087; Supplementary Fig. S3E).
These findings were confirmed in the mouse model display-
ing a correlation between circulating and intratumor miR-221
levels in untreated animals (Pearson correlation: R ¼ 0.66; P ¼
0.048; Fig. 2B).
Subsequently, we tested circulating miR-221 levels in the
setting of sorafenib treatment in both models. Sorafenib treated
DEN-HCC rats displayed an inverse correlation between circulat-
ing and tissuemiR-221 levels (Pearson correlation: R¼0.75;P¼
0.050; Fig. 2C). This finding suggests that sorafenib might have a
role in miR-221 release from neoplastic hepatocytes into the
bloodstream. The same result was confirmed in themousemodel,
displaying a negative correlation between circulating miR-221
levels and both tissue miR-221 levels (Pearson correlation: R ¼
0.88; P ¼ 0.047) and tumor size (Pearson correlation: R ¼
0.96; P ¼ 0.003; Fig. 2D and E).
We next explored the mechanisms contributing to miR-221
release into the bloodstream in basal conditions as well as
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Figure 1.
MiR-221 correlates with sorafenib resistance in HCC animal models. A, qPCR analysis of miR-221 expression in 16 DEN-treated rats and two healthy controls (Ctrl).
Each nodule was compared with the surrounding liver parenchyma (NL). The y-axis reports the 2DDCt values corresponding to miR-221 expression. B and C,
Box plot graphic representation of miR-221 and EPCAMmRNA expression in DEN-treated rats following 21 days of sorafenib administration ("ratþ sorafenib"). HCC
nodules were divided in responders (R) and nonresponders (NR) based on US imaging and histopathologic examination. The y-axis reports the 2DDCt values
corresponding to gene expression (log2 form). D and E, Box plot graphic representation of tumor size or tumor doubling time in sorafenib-treated or untreated
xenograft mice obtained following subcutaneous injection of Huh-7 cells into the flank of nude mice ("xenograft"). The treated group received sorafenib
intragastrically for 21 days; the untreated group received only the vehicle. The y-axis represents tumor size (mm3) or tumor doubling time (days). F,Correlation graph
between tumor size and miR-221 expression in sorafenib-treated xenograft mice. The xenograft model was obtained by subcutaneous injection of Huh-7
cells, and once the tumors reached a volume of 40–50 mm3, mice received sorafenib intragastrically for 21 days ("xenograft þ sorafenib"). The x-axis reports the
2DDCt values corresponding to miR-221; y-axis represents tumor size (mm3). All values are transformed in a log2 form.
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following sorafenib. Eight HCC-derived cell lines were assayed,
and a correlation between miR-221 levels in cell culture super-
natant and exosome fraction was found, suggesting exosome
vesicles as a source of circulating miR-221 (Pearson correlation:
R¼ 0.928; P¼ 0.001), as previously demonstrated by us in HCC
patients (23).
In HCC cells, sorafenib increased miR-221 levels in cell
culture supernatant (Student t test: P ¼ 0.01; Fig. 2F), as well
as in its exosomal fraction (Student t test: P ¼ 0.009; Fig. 2G),
while miR-221 levels decreased in the intracellular compart-
ment (Student t test: P¼ 0.02; Fig. 2H). These findings suggest a
direct role of sorafenib in the variation of miR-221 expression
in both the intracellular and extracellular compartments in
HCC. To evaluate which molecular pathway modulated by
sorafenib was mainly involved in miR-221 secretion from the
intra to the extracellular compartment, we tested eight HCC-
derived cell lines with three inhibitors of molecular path-
ways modulated by sorafenib (PLX-4720 inhibiting BRAF,
RAF1, and CRAF; ZM323881 inhibiting VEGFR2; GDC-0941
inhibiting PI3Ka/d). We compared miR-221 changes in the
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extracellular compartments in treated versus untreated cells.
PLX-4720 administration, inhibiting the Ras/Raf/Mek/Erk
pathway, determined an increase in miR-221 extracellular
levels in SNU475 cells only, while no relevant increase was
detected in the other cell lines. Similarly, no significant increase
was observed following VEGFR2 inhibition, obtained by
ZM323881 administration, in all the cell lines. The inhibition
of PI3Ka/d was performed due to the relevant role of pAKT in
exosomal trafficking in cancer cells. Because a high heteroge-
neity was found in constitutive activation of the MAPK and
PI3K–Akt pathways, HCC-derived cell lines were evaluated
taking into account basal expression levels of each pathway
and the extent of miR-221 variations following treatments.
Sorafenib administration determined miR-221 extrusion from
the intra to the extracellular compartment in HepG2 (with the
most relevant effect), Hep3B, Huh-7, SNU398, SNU182, and
PLC cells, but not in SNU475 and SNU449 cells. Notably,
following sorafenib treatment, an opposite phosphorylation
pattern of Akt was observed in HepG2 versus SNU449 and
SNU475 cells. Therefore, we hypothesized that pAkt levels
might be relevant as far as miR-221 release from HCC cells is
concerned (Fig. 2I). A relevant increase of miR-221 extracellular
levels was observed by PI3K inhibition in SNU449 and
SNU475 cells. The effects on miR-221 extrusion in HepG2,
SNU449, and SNU475 cells treated by sorafenib was thus
opposite to what observed following GDC-0941. GDC-0941
treatment was not able to reduce pAkt levels in HepG2 cells
where no variation of miR-221 extracellular levels was detected,
whereas it reduced pAkt levels in SNU449 and SNU475 cells
where an increase of miR-221 extrusion was detected (Fig. 2J).
Thus, we can speculate that the inhibition of the PI3K–pAkt axis
by GCD-0941 might be responsible for miR-221 extrusion in
these cells. Notably, the extent of sorafenib treatment in miR-
221 secretion is higher than that observed after PI3K inhibition,
thus supporting the contribution of other molecular events.
High circulatingmiR-221 levels are associated with response to
sorafenib in HCC patients.
As described above, both rodent models suggested that higher
miR-221 tissue levels were associated with sorafenib resistance.
Conversely, higher circulating miR-221 levels correlated with
smaller tumor size and inversely correlated with tissue miRNA
levels. These findings prompted us to assay circulating miR-221
levels in sorafenib-treated HCC patients.
To test miR-221 as a possible circulating biomarker predicting
the likelihood of response to sorafenib, we analyzed miR-221
levels in sera from HCC patients before sorafenib treatment.
Patients experiencing radiologic disease progression (N ¼ 27)
showed higher pretreatmentmiR-221 levels when comparedwith
responders (N¼ 23), as assessed at 2monthsCT/MR examination
(t test: P ¼ 0.007; Fig. 3A). Among the 50 patients tested before
treatment start, 28 patients (12 responders and 16 nonrespon-
ders) were further tested at 2months follow-up.When comparing
pretreatment and on-treatment miR-221 levels in the same
patient, an increase of miR-221 levels was detected in responders
(paired t test: P ¼ 0.042; Fig. 3B), whereas a nonsignificant
decrease of miR-221 levels was registered in nonresponders
(paired t test: P ¼ 0.058).
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Figure 3.
Circulating miR-221 in patients with
advanced HCC treated with sorafenib.
A, Basal miR-221 levels in patients
responding or nonresponding to
sorafenib treatment, as assessed at the
twomonthsCT/MRexamination, in the
training set. B, Circulating miR-221
levels assessed before sorafenib start
and at the two months follow-up in
patients responding to sorafenib in the
training set. C, Circulating miR-221
levels in patients responding or non-
responding to sorafenib, as assessed at
the 2 months CT/MR examination, in
the validation set. D, Circulating miR-
221 levels assessed before sorafenib
start and at the 2 months follow-up in
patients responding to sorafenib in the
validation set. A and C, Unpaired
Student t test was considered for
statistical analysis. B and D, Paired
Student t test was considered for
statistical analysis. A–D, RNU6B was
used as housekeeping gene for QPCR
analysis. Y-axes report 2DDCt values
corresponding to circulating miR-221
levels. Pretreatment: circulating miR-
221 levels were evaluated in sera
samples collected before treatment.
On-treatment: circulating miR-221
levels were evaluated in sera samples
collected at 2 months CT/MR
assessment.
Fornari et al.
Clin Cancer Res; 23(14) July 15, 2017 Clinical Cancer Research3958
on June 12, 2019. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst January 17, 2017; DOI: 10.1158/1078-0432.CCR-16-1464 
An independent small validation cohort of 43 advanced
HCC patients enrolled by the Department of Medical Oncology
of the Meldola's Cancer Center and by the Bologna's Center was
assessed for circulating miR-221 before treatment start and at
the 2 months follow-up in 31 of 43 patients. Even though the
number of patients included is too small to draw any conclu-
sion, this validation series confirmed the findings obtained in
the training set, as shown in Fig. 3C. The 26 patients experienc-
ing a partial response or disease progression at 2 months
displayed higher miR-221 serum levels when compared with
the 17 patients with a stable disease (t test, P ¼ 0.04). Among
the 17 responders, 14 patients were assessed also at the 2
months follow-up, and an increase of miR-221 circulating
levels was confirmed when compared with miR-221 pretreat-
ment levels (paired t test, P ¼ 0.05). As observed in the training
set, a nonsignificant reduction of miR-221 serum levels at the 2
months follow-up was observed in 17 of 26 tested nonrespond-
er patients (paired t test, P ¼ 0.07). In conclusion, lower
pretreatment miR-221 serum levels are associated with
response to sorafenib. In addition, treatment response was
associated with an increase of circulating miR-221, suggesting
a possible secretion of this onco-miRNA from the intracellular
compartment of neoplastic cells.
MiR-221 decreases apoptosis in sorafenib-treated HCC cell
lines
To study miR-221 involvement as a possible contributor to
sorafenib resistance, HCC-derived cells were transfected with pre-
or anti-miR-221 and treated with sorafenib for 48 hours.
Specifically, we chose Huh-7 and Hep3B cells for miR-221
overexpression because of their low miR-221 basal levels, while
miR-221 silencing was performed in SNU449 and SNU182 cells
due to their high miR-221 basal levels, as previously reported
(14). Transient miR-221 overexpression in sorafenib-treated
Huh-7 and Hep3B cells increased cell viability (Student t test:
P ¼ 0.04 and P ¼ 0.017, respectively) and decreased caspase 3/7
activity (Student t test: P¼ 0.006 and P¼ 0.033, respectively) and
expression (Fig. 4A and B). A similar effect was observed inHuh-7
cells stably overexpressing miR-221, indicating that even a low
miR-221 increase (6.5-fold) is sufficient to reduce sorafenib
Figure 4.
MiR-221 decreases sorafenib activity in HCC cell lines. A and B, Cell viability assay, caspase 3/7 activity assay, and Western blot analysis in transient miR-221
overexpressing Huh-7 and Hep3B cells subjected to sorafenib. C, Cell viability assay, caspase 3/7 activity assay, and Western blot analysis in Huh-7 cells
stably infectedwith pMXs-miR-221 overexpression vector subjected to sorafenib treatment.D and E,Cell viability assay, caspase 3/7 activity assay, andWestern blot
analysis in transient miR-221 silenced SNU182 and SNU449 cells following sorafenib treatment. F, Annexin V cytofluorimetric analysis in miR-221 stably
overexpressing Huh-7 cells subjected to sorafenib treatment. A–F, NC: pre-miR–negative control; NCi: anti-miR–negative control; AM-221: anti-miR-221; shRNA:
scramble short hairpin RNA control vector. A–E, b-actin was used to normalize WB data.
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anticancer activity (Student t test: P ¼ 0.0008 and P ¼ 0.002 for
cell viability and caspase assay, respectively; Fig. 4C). Conversely,
miR-221 silencing in sorafenib-treated SNU182 and SNU449
cells decreased cell viability (Student t test: P ¼ 0.03 and
0.001, respectively) and increased caspase 3/7 activity (Student
t test: P ¼ 0.003 and 0.016, respectively) and expression (Fig. 4D
and E). Notably, miR-221 did not alter Bax and Puma protein
expression in all the cell lines except Hep3B (Fig. 4A–E), suggest-
ing a main involvement of the caspase cascade in miR-221–
mediated sorafenib resistance. FACS–Annexin V assay performed
in stably overexpressingmiR-221Huh-7 cells following sorafenib
challenge further confirmed these data. A 1.4-fold decrease of
events in late apoptosis was detected in miR-221 overexpressing
cells (Student t test: P ¼ 0.01; Fig. 4F). These data highlighted an
involvement of miR-221 in sorafenib resistance of HCC cells,
associated with inhibition of the caspase signaling.
MiR-221 targets caspase-3 in HCC cell lines
To clarify mechanisms sustaining miR-221 involvement in
sorafenib resistance, a computational analysis was performed
identifying CASP3 (NM_004346) among its target genes
(TargetScan and MiRanda algorithms; Fig. 5A). To identify the
best in vitro models to study caspase-3 regulation by miR-221,
their expression levels were assayed in HCC-derived cell lines.
An inverse correlation was found between miR-221 and cas-
pase-3 mRNA and protein levels (Spearman correlation P ¼
0.036; Fig. 5B).
The functional analysis was performed based on miR-221
basal levels in HCC cells. HepG2 and Huh-7 cells were chosen
for miR-221 overexpression, whereas SNU449 and SNU182
cells were selected for miR-221 silencing. Cell transfection of
pre-miR-221 in HepG2 and Huh-7 cells reduced caspase-3
expression at both protein and mRNA levels. The same was
confirmed in Huh-7 cells stably overexpressing miR-221, by
retroviral infection (Fig. 5C–E). Conversely, anti-miR-221
transfection in SNU449 and SNU182 cells increased both
caspase-3 mRNA and protein expression (Fig. 5F and G). To
prove a direct interaction between miR-221 and its target gene,
the 30UTR region of caspase-3 mRNA was cloned downstream a
reporter gene and the resulting vector (pGL3-casp-3) was
employed in a dual-luciferase assay. Cotransfection of pGL3-
casp-3 vector with miR-221 in HepG2 cells or with AM-221 in
SNU449 cells caused a 1.5-fold decrease and a 1.6-fold increase
of the luciferase activity, respectively (Student t-test: P ¼ 0.007
and P ¼ 0.001, respectively; Fig. 5H). Finally, to demonstrate
that caspase-3 targeting is an important mechanism mediating
sorafenib resistance by miR-221, SNU449 cells were cotrans-
fected with anti-miR-221 oligonucleotides and caspase-3 siR-
NAs and subsequently treated with sorafenib. WB analysis
showed that caspase-3 inhibition was able to counteract the
activation of the caspase cascade triggered by miR-221 silenc-
ing, decreasing the levels of cleaved fractions of caspase-3,
caspase-7, and PARP, with respect to anti-miR-221–only trans-
fected cells (Fig. 5I). These data demonstrated that miR-221
directly modulates caspase-3 expression in HCC cells by mRNA
degradation and that caspase-3 targeting is involved, at least in
part, in miR-221–mediated sorafenib resistance.
MiR-221 regulates caspase-3 expression in vivo
To confirm the regulation of caspase-3 by miR-221, a liver-
specific miR-221 transgenic (TG) mouse model (13) was used.
Caspase-3 protein levels were quantified by WB analysis in liver
samples from 25 TG and 16 wild-type (WT) animals. A 1.4-fold
decrease of caspase-3 expression was observed in TG mice with
respect to WT controls (Student t test: P ¼ 0.022; Fig. 6A and B).
Moreover, to demonstrate that miR-221 was able to regulate
caspase-3 expression in vivo, we performed miR-221 silencing in
this TG mouse model by means of chemically modified oligo-
nucleotides (13). A mean 2.0-fold increase of caspase-3 protein
levels was detected in liver tissue of anti-miR-221-treated mice
with respect to the control group (Fig. 6C). Furthermore, we
observed that caspase-3 upregulation was maintained in anti-
miR-221–treated animals also following sorafenib administra-
tion in comparison with vehicle-treated mice. In vivo miR-221
silencing was verified in both settings by QPCR analysis
(Fig. 6D). These findings proved the caspase-3 targeting by
miR-221 in vivo and suggested that this molecular mechanism
might contribute to sorafenib resistance in miR-221–overex-
pressing HCCs.
MiR-221 and caspase-3 correlation was also investigated in the
tumor tissue from the DEN-induced HCC rat model. As reported
in Fig. 1A, when comparing HCC versus its matched surrounding
liver tissue, miR-221 expression increased in 65% of HCC tissues,
while caspase-3 mRNA and protein levels decreased in 70% and
50% of HCC nodules, respectively. An inverse correlation
between miR-221 and caspase-3 was observed at both mRNA
andprotein levels in ratHCCs (Pearson correlation:P¼0.009 and
0.04, respectively; Fig. 6E and F; Supplementary Fig. S3F). We
previously demonstrated that miR-221 regulates apoptosis
through Bmf targeting (3). Here, we confirm an inverse correla-
tion between miR-221 and Bmf mRNA (Pearson correlation: R¼
0.53, P ¼ 0.008) and a positive correlation between Bmf and
caspase-3mRNA (Pearson correlation: R¼ 0.71, P<0.0001) in rat
HCCs, suggesting that miR-221 regulates apoptosis through a
multitarget activity (Supplementary Fig. S3G and S3H). In vitro
experiments confirmed the ability of miR-221 to target contem-
poraneously caspase-3 and Bmf proteins in transfected HepG2
and SNU449 cells. Moreover, the silencing of caspase-3 slightly
decreased Bmf protein levels (Supplementary Fig. S3I), letting us
to hypothesize a complex interplay among miR-221 and these
two proapoptotic targets.
Finally, we investigated the relationship between miR-221 and
caspase-3 levels in 60 patients surgically resected for HCC. An
inverse correlation between miR-221 and its target gene is shown
in Fig. 6G (Pearson correlation: R ¼ 0.45, P < 0.0001). In line
with the HCC rat model, a mean 3.0-fold increase of miR-221
levels was detected in HCC samples with respect to matched
cirrhotic livers, whereas similar miR-221 levels were quantified in
normal livers and nontumor samples. In addition, comparable
miR-221 levels were observed inHCC patients andHCC cell lines
with lowbasal levels (HepG2,Hep3B, andHuh-7; Supplementary
Fig. S3L). As previously reported, high miR-221 levels were
associated with HCCmultifocality (Student t test, P ¼ 0.013; Fig.
6H; refs. 3). Here, we also report an association between reduced
caspase-3 expression and HCC multifocality (Student t test, P ¼
0.02; Fig. 6I). Moreover, we investigated the possible associations
between miR-221 and caspase-3 expression and tumor character-
istics. No association betweenmiR-221 or caspase-3mRNA levels
and clinicopathologic features (AFP serum levels, tumor size,
etiology, and grading) was detected in this cohort of surgically
resectedpatients (Supplementary Fig. S4). These data confirm that
miR-221 and caspase-3 aberrant expression in HCC is associated
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Figure 5.
MiR-221 targets caspase-3 in HCC. A, MiR-221 hypothetical binding site in caspase-3 30UTR as shown by MiRanda and TargetScan algorithms. Stars represent
the mutagenized basis in the reporter assay. B, QPCR and WB analyses of miR-221 and caspase-3 levels in HCC-derived cell lines. The y-axis reports the
2DDCt values corresponding tomiR-221 or caspase-3mRNA levels. Correlation graphs represent the relationship betweenmiR-221 and caspase-3mRNA and protein
levels. All the values are in a log2 form. C, Western blot, RT-PCR, and QPCR analyses in miR-221 overexpressing HepG2 cells. D and E, Western blot, RT-PCR,
and QPCR analyses in transient and stable miR-221 overexpressing Huh-7 cells. F and G,Western blot, RT-PCR and QPCR analyses in miR-221 silenced SNU449 and
SNU182 cells. B–G, b-actin was used to normalize PCR and WB data. C–G, Bar charts below WB images display mean  SD values relative to immunoblot
quantification of three different replicates. Bar charts below RT-PCR images represent mean  SD values relative to QPCR analysis. H, Luciferase reporter assay in
HepG2 andSNU449 cells cotransfectedwithWTormutatedpGL3-casp3 vector andmiR-221 orAM-221. I,Westernblot analysis of apoptoticmarkers in cotransfected
SNU449 cells subjected to sorafenib treatment. b-Actin was used as housekeeping gene. C–I, pGL3: empty reporter vector; NC: pre-miR–negative control;
NCi: anti-miR–negative control; AM: anti-miR-221; shRNA: scramble short hairpin RNA control vector; scr: scramble oligonucleotides; si: small interfering RNAs.
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with tumor multinodularity but is independent from other clin-
ical variables.
Discussion
The oncogenic function of miR-221 in hepatocarcinogenesis is
well documented (13, 19, 24). Similarly, its role in the regulation
of cell proliferation, apoptosis (1, 3, 5), and treatment resistance
(14–16) was previously ascertained. In an orthotopic mouse
model of HCC, Park demonstrated the therapeutic efficacy of
miR-221 inhibition, suggesting miR-221 as a target in patients
with HCC (26). These findings were confirmed in our transgenic
HCC mouse model, in which anti-miR-221 systemic treatment
reduced number and size of HCC nodules (13).
MiRNAs modulation triggered significant effects in the
response to anticancer treatments in different cancers. Specif-
ically, miR-221 overexpression in HER-2–positive breast can-
cer cells inhibited apoptosis and promoted metastasis and
trastuzumab resistance by targeting PTEN. This study sug-
gested a role of miR-221 as a potential biomarker for the
assessment of progression and poor prognosis, as well as a
novel target for trastuzumab-combined treatment for HER2-
positive breast cancer (27). Similarly, miR-221 silencing sen-
sitized HCC and NSCLC cells to TRAIL by regulating PTEN and
TIMP3 (16). A recent study reported miR-221 involvement in
dexamethasone resistance through PUMA downregulation in
multiple myeloma, suggesting miR-221 as a marker of prog-
nosis and clinical response in this context (28). Here, we report
miR-221 overexpression in HCC tissue as a molecular event
associated with resistance to sorafenib in two HCC animal
models. In particular, in the chemically induced HCC rat
model an association between high miR-221 intratumor levels
and sorafenib resistance was observed, whereas in the xeno-
graft mouse model a direct correlation between miR-221 levels
and tumor size was registered. We also demonstrated that
caspase-3 is a direct target of miR-221 in HCC, further suggest-
ing miR-221 inhibition as a therapeutic approach aimed to
contrast resistance to sorafenib. A recent study describes an
inverse correlation between caspase-3 and miR-221 in several
cancer cell lines (29), but no clear evidence of a direct targeting
was provided. Therefore, to our knowledge, this is the first time
that caspase-3 is shown to be directly modulated by miR-221
in HCC. Moreover, here we showed a complex regulatory
network between miR-221 and its two proapoptotic targets,
caspase-3 and Bmf. Indeed, we confirmed our previous find-
ings (3) reporting a mutual regulation between Bmf and
caspase-3 expression and activation in in vitro models and we
identified a positive correlation between them in preclinical
animal models. We might speculate that both targets are
important for miR-221 biological activity and that the prev-
alence of one of them might be dependent on cell context,
basal levels, and type of apoptotic stimuli.
A clinical challenge in the oncology field is represented by
the identification of non-invasive biomarkers to be used for
the prognostic stratification and for the personalization of
treatments. Here, we describe an association between miR-
221 circulating levels and response to sorafenib in animal
models and in patients with advanced HCC undergoing
sorafenib treatment. An inverse correlation between miR-
221 serum levels (at the end of treatment) and tumor size
was detected in treated animals, letting us to hypothesize low
miR-221 circulating levels as a possible biomarker of sorafe-
nib resistance. In HCC patients, sorafenib treatment deter-
mined an increase of miR-221 circulating levels only in
responders. Conversely, before sorafenib start, lower miR-
221–circulating levels, assessed at baseline, were associated
with response to treatment. Even though the patient cohorts
tested here are too small to draw any conclusion, circulating
miR-221 might deserve attention as a candidate noninvasive
biomarker of response to sorafenib to be tested in prospective
trials.
Because sorafenib treatment influences miR-221 intratumoral
and circulating levels, we next investigated the mechanisms
sustaining miR-221 secretion from neoplastic cells, by exploring
the effects of sorafenib in HCC-derived cell lines. Sorafenib
administration determined the extrusion of miR-221 from HCC
cells into cell culture supernatant in an exosome-dependent
manner, determining a reduction of its intracellular levels.
Because several proapoptotic factors, such as BMF, BIM, and
PUMA, are miR-221 targets (3, 30, 31), the secretion of this
oncomiRNA in the extracellular compartment might decrease its
intracytoplasmic levels, thus reducing its antiapoptotic activity
and sensitizing HCC cells to sorafenib. These events were dem-
onstrated in HCC cells, and we can hypothesize that a similar
mechanism might occur in primary tumors, even though we
cannot exclude that the tumor surrounding tissue or tumor
infiltrating cells can contribute tomiR-221 release into the blood-
stream. Although we cannot provide a direct demonstration of
miR-221 provenience, findings obtained from two animal mod-
els, cell lines, and a restricted series of patientswith advancedHCC
Figure 6.
MiR-221 targets caspase-3 in vivo. A, Western blot analysis of caspase-3 expression in miR-221 liver-specific transgenic (TG) and WT mice (representative
cases). b-Actin was used as housekeeping gene. Numbers represent the densitometric analysis of WB bands normalized for the housekeeping gene. The bar chart
below WB image displays mean  SD values relative to immunoblot quantification of three different replicates. B, Box plot graph of caspase-3 expression
in TG and WT mice. The y-axis reports the 2DDCt values corresponding to caspase-3 expression. C, Western blot and QPCR analyses of caspase-3 and miR-221
expression in TG mice treated with anti-miR-221 oligonucleotides (AM-221) or with vehicle (representative cases). D, Western blot and QPCR analyses
of caspase-3 andmiR-221 expression in TGmice treatedwith anti-miR-221 oligonucleotides (AM-221) orwith vehicle and subjected to sorafenib administration.C and
D, b-Actin was used as a housekeeping gene. Numbers represent the densitometric analysis of WB bands normalized for the housekeeping gene. The
bar charts belowWB images display mean SD values of caspase-3 expression in the two mice groups. E and F, Negative correlation between miR-221 expression
and caspase-3 mRNA (N ¼ 24) or caspase-3 protein (N ¼ 23) levels in the DEN-HCCs. The x and y-axes report the 2DDCt values corresponding to miR-221
levels and caspase-3 mRNA or protein levels (log2 form).G,Negative correlation betweenmiR-221 expression and caspase-3 mRNA (N¼ 60) levels in human HCCs.
The x and y-axes report the 2DDCt values corresponding to miR-221 and caspase-3 mRNA levels (log2 form). H and I, Box plot graph of miR-221 and
caspase-3 expression in unifocal (UNI) and multifocal (MULTI) human HCCs. The y-axis reports the 2DDCt values corresponding to miR-221 or caspase-3 expression
(log2 form). B-actin was used for WB and qPCR normalization.
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are consistent with its role as a candidate biomarker of likelihood
of response to sorafenib, as well as a noninvasive and dynamic
assay to be validated in prospective clinical studies in HCC
patients.
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